ClinicalTrials.gg
Active, not recruitingNCT04020055Updated Jul 6, 2026

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

A Phase 3 interventional study of migalastat HCl 150 mg in Fabry Disease, sponsored by Amicus Therapeutics. Active, not recruiting at 12 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Planned enrollment
14th of 20
14 · median 20
Started
2022
the only one that year
Phase 3
11 of 20
2 open now
Registered
17th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 14th largest by planned enrollment, is the only one that started in 2022, is one of 11 in phase 3, and was the 17th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)

Read the detailed description

This is an open-label, non-comparative study for subjects with Fabry disease who have an estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease equation (eGFRMDRD) value of \< 30 mL/min/1.73 m2. Subjects may have had previous exposure to migalastat, either commercially or as a participant in a previous migalastat study.

Two distinct populations of subjects with Fabry disease and renal impairment will be enrolled into this study:

  • Cohort 1: Subjects with SRI not receiving any type of dialysis treatment
  • Cohort 2: ESRD subjects who are receiving hemodialysis treatment, either standard hemodialysis (HD) or hemodiafiltration (HDF). Only subjects who can receive HD/HDF at the study clinic or at an affiliated center where the Investigator already has oversight should be enrolled into Cohort 2.

Subjects entering into this study will undergo screening (Visit 1) to confirm enrollment eligibility including confirmatory GLA genotyping. Subjects who meet eligibility criteria will have a Baseline Visit (Visit 2) within 30 days of screening. Subjects who do not meet eligibility criteria (eg, subjects with an eGFR > 30 mL/min/1.73 m2) may be re-screened.

03

Conditions studied

  • Fabry Disease

Keywords

  • Renal Disease
  • Severe Renal Impairment (SRI)
  • End-Stage Renal Disease (ESRD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 years or older, diagnosed with Fabry disease.
  2. Subject (or legally authorized representative as applicable) is willing and able to provide written and authorization for use and disclosure of Personal Health Information
  3. Subject has a GLA variant that is amenable to migalastat recorded in their medical records
  4. Subject has at least 1 documented value of \< 30 mL/min/1.73 m2 within the last 3 months and has an eGFRMDRD value of \< 30 mL/min/1.73 m2 at Visit 1
  5. Subjects with ESRD have been on a stable 2- or 3-times a week HD (standard or HDF) regimen for at least 2 months prior to the screening visit
  6. Subjects with ESRD must commit to completing at least 4 standard HD or HDF sessions during each 2-week dosing interval.
  7. Subjects with ESRD must commit to completing the entire prescribed duration for each dialysis session.
  8. If of , both male and female patients agree to use a medically accepted method of

Exclusion criteria

Exclusion Criteria:

  1. Subject has undergone kidney transplantation
  2. Subject is on peritoneal dialysis
  3. Subject is treated or has been treated with another drug (except migalastat) within the 30 days
  4. Subject has undergone any gene therapy at any time prior to the study or anticipates undergoing gene therapy during the study.
  5. Subject has had a documented , stroke, unstable angina, or myocardial infarction
  6. Subject has unstable cardiac disease
  7. Subject has any intercurrent illness or condition that may preclude the subject from fulfilling the protocol requirements
  8. Subject has a history of allergy or sensitivity to migalastat (including ) or other iminosugars (eg, miglustat, miglitol)
  9. Subject requires concurrent treatment with Glyset® (miglitol), Replagal® (agalsidase alfa), or Fabrazyme® (agalsidase beta)
  10. Subject requires concurrent treatment with Zavesca® (miglustat) or has been treated with Zavesca
  11. Female subject is pregnant or breast-feeding
  12. Subject is unable to comply with study requirements
  13. In France only, protected persons as defined by the Public Health Code
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Severe Renal Impairment

    All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.

  • Experimental
    Cohort 2: End-Stage Renal Disease

    All hemodialysis subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat). Subjects will take 1 migalastat capsule orally with water every other week.

    Drug: migalastat HCl 150 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  2. Time to maximum concentration (tmax)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  3. Apparent terminal elimination half-life (t½)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK

    Time frame: Baseline through Month 12

  4. Concentration at the end of a dosing interval at steady state (Ctrough)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  5. Average plasma migalastat concentration over the dosing interval (Cavg)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  6. Area under the concentration-time curve at steady state during the dosing interval (AUC0-τ)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  7. Area under the concentration-time curve from zero time (pre-dose) extrapolated to infinite time (AUC0-∞)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  8. Apparent plasma clearance (CL/F)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK

    Time frame: Baseline through Month 12

  9. Apparent terminal phase volume of distribution (Vz/F)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  10. Dialysis clearance (CLD)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  11. Volume of dialysate collected during the interval (VD)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  12. Mean migalastat concentration in dialysate (CD)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  13. Amount recovered in dialysate (AeD)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  14. Fraction of the dose recovered in dialysate (FeD)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  15. Mean migalastat plasma concentration during the dialysis interval (P)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  16. Mean inlet area under the curve (AUCinlet)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  17. Mean outlet area under the curve (AUCoutlet)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  18. Extraction ratio (ED)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  19. Dialyzer blood flow (QD)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  20. Cumulative amount excreted over all collection intervals (Ae0-τ)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  21. Fraction of the dose recovered after the last measurable time point postdose (Fe0-τ)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

  22. Renal clearance (CLr)

    To characterize the pharmacokinetics (PK) of migalastat and validate the population PK (popPK) model and simulations.

    Time frame: Baseline through Month 12

Secondary outcomes

  1. Adverse events (AEs)

    To assess the safety and tolerability of migalastat in Fabry subjects with severe renal impairment and end stage renal disease.

    Time frame: Baseline through Month 12

  2. Change from baseline in estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease equation (eGFR MDRD)

    To assess the safety and tolerability of migalastat in Fabry subjects with severe renal impairment and end stage renal disease

    Time frame: Baseline through Month 12

  3. Change from baseline eGFR based on the Chronic Kidney Disease Epidemiology Collaboration equation (eGFRCKD-EPI)

    To assess the safety and tolerability of migalastat in Fabry subjects with severe renal impairment and end stage renal disease

    Time frame: Baseline through Month 12

  4. Change from baseline in plasma globotriaosylsphingosine (lyso-Gb3)

    To evaluate the pharmacodynamics (PD) of migalastat in subjects with Fabry disease and severe renal impairment

    Time frame: Baseline through Month 12

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.

Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2019
First posted
Jul 15, 2019
StartActual
Oct 31, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04020055
Responsible party
Sponsor
First posted
Jul 15, 2019
Start date
Oct 31, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion